Prague Med. Rep. 2025, 126, 121-138
https://doi.org/10.14712/23362936.2025.20
Development, Implementation, Pharmacokinetic and Safety Evaluation of an Immunotherapeutic Treatment for COVID-19: Double-blind Randomized Placebo-controlled Trial
Guillermo Alberto Keller1,2,3
, Silvia Miranda3, Adolfo Rafael De Roodt1, Roxana Salvi2, Ivana Colaianni2, Elizabeth García2, Guillermo Bramuglia3, Leandro Calderón1, Diego Mazza1, Laura Lanari1, Oscar Perez1, Matias Fingermann1, Guillermo Temprano1, Guillermo Di Girolamo3, Claudio Bonel1, José Cristian Dokmetjian1
, Silvia Miranda3, Adolfo Rafael De Roodt1, Roxana Salvi2, Ivana Colaianni2, Elizabeth García2, Guillermo Bramuglia3, Leandro Calderón1, Diego Mazza1, Laura Lanari1, Oscar Perez1, Matias Fingermann1, Guillermo Temprano1, Guillermo Di Girolamo3, Claudio Bonel1, José Cristian Dokmetjian1
1Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS-Malbrán), Instituto Nacional de Producción de Biológicos (INPB), Buenos Aires, Argentina
2Hospital General de Agudos Donación Francisco J. Santojanni, Buenos Aires, Argentina
3Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
Received January 21, 2025
Accepted August 27, 2025
References
1. , H., Eshghi, P., Cheraghali, A. M., Imani Fooladi, A. A., Bolouki Moghaddam, F., Imanizadeh, S., Moeini Maleki, M., Ranjkesh, M., Rezapour, M., Bahramifar, A., Einollahi, B., Hosseini, M. J., Jafari, N. J., Nikpouraghdam, M., Sadri, N., Tazik, M., Sali, S., Okati, S., Askari, E., Tabarsi, P., Aslani, J., Sharifipour, E., Jarahzadeh, M. H., Khodakarim, N., Salesi, M., Jafari, R., Shahverdi, S. (2020) Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus. Apher. Sci. 59(5), 102875.
<https://doi.org/10.1016/j.transci.2020.102875>
2. , J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J. S., Roh, J., Ahn, M. Y., Chin, B. S., Kim, Y. S., Lee, H., Yong, D., Kim, H. O., Kim, S., Choi, J. Y. (2020) Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J. Korean Med. Sci. 35(14), e149.
<https://doi.org/10.3346/jkms.2020.35.e149>
3. , J., Barraviera, B., Calvi, S., Carvalho, R., Peracoli, M. (2006) Antibody and cytokine serum levels in patients subjected to anti-rabies prophylaxis with serum-vaccination. J. Venom. Anim. Toxins Incl. Trop. Dis. 12(3), 435–455.
<https://doi.org/10.1590/S1678-91992006000300008>
4. , C., Herbreteau, C. H., Buchy, P., Rith, S., Zaid, M., Kristanto, W., Han, V., Reynaud, C., Granjard, P., Lépine, B., Durand, C., Tambyah, P. A. (2015) Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab’)2 fragments against avian influenza A (H5N1) in healthy volunteers: A single-centre, randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect. Dis. 15(3), 285–292.
<https://doi.org/10.1016/S1473-3099(14)71072-2>
5. , J. H., Aga, E., Elie-Turenne, M. C., Cho, J., Tebas, P., Clark, C. L., Metcalf, J. P., Ozment, C., Raviprakash, K., Beeler, J., Holley, H. P. Jr., Warner, S., Chorley, C., Lane, H. C., Hughes, M. D., Davey, R. T. Jr.; IRC005 Study Team (2019) Anti-influenza immune plasma for the treatment of patients with severe influenza A: A randomised, double-blind, phase 3 trial. Lancet Respir. Med. 7(11), 941–950.
<https://doi.org/10.1016/S2213-2600(19)30199-7>
6. , E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., Pekosz, A., Lau, B., Wesolowski, A., Katz, L., Shan, H., Auwaerter, P. G., Thomas, D., Sullivan, D. J., Paneth, N., Gehrie, E., Spitalnik S., Hod, E. A., Pollack, L., Nicholson, W. T., Pirofski, L., Bailey, J. A., Tobian, A. A. (2020) Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. 130(6), 2757–2765.
<https://doi.org/10.1172/JCI138745>
7. , W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., Han, Y., Lin, L., Ruan, L., Li, T. (2020) High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect. Dis. 7(3), ofaa102.
<https://doi.org/10.1093/ofid/ofaa102>
8. , A. (2002) Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8(8), 833–841.
<https://doi.org/10.3201/eid0808.010516>
9. , L., Xiong, J., Bao, L., Shi, Y. (2020) Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20(4), 398–400.
<https://doi.org/10.1016/S1473-3099(20)30141-9>
10. , A., Addesi, D., Cavallo, M., Spagnolo, F., Suraci, E., Cordaro, R., Spinelli, I., Passafaro, F., Colosimo, M., Pintaudi, M., Pintaudi, C.; On Behalf Of The CATAnzaro LOng Covid Cataloco Study Group (2022) Monoclonal antibodies and antivirals against SARS-CoV-2 reduce the risk of long COVID: A retrospective propensity score-matched case-control study. Biomedicines 10(12), 3135.
<https://doi.org/10.3390/biomedicines10123135>
11. , R. T. Jr., Fernández-Cruz, E., Markowitz, N., Pett, S., Babiker, A. G., Wentworth, D., Khurana, S., Engen, N., Gordin, F., Jain, M. K., Kan, V., Polizzotto, M. N., Riska, P., Ruxrungtham, K., Temesgen, Z., Lundgren, J., Beigel, J. H., Lane, H. C., Neaton, J. D.; INSIGHT FLU-IVIG Study Group (2019) Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): A double-blind, randomised, placebo-controlled trial. Lancet Respir. Med. 7(11), 951–963.
<https://doi.org/10.1016/S2213-2600(19)30253-X>
12. , J., Heybati, K., Ramaraju, H. B., Zhou, F., Rayner, D., Heybati, S. (2023) Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: A systematic review and network meta-analysis. Infection 51(1), 21–35.
<https://doi.org/10.1007/s15010-022-01825-8>
13. , K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., Peng, C., Yuan, M., Huang, J., Wang, Z., Yu, J., Gao, X., Wang, D., Yu, X., Li, L., Zhang, J., Wu, X., Li, B., Xu, Y., Chen, W., Peng, Y., Hu, Y., Lin, L., Liu, X., Huang, S., Zhou, Z., Zhang, L., Wang, Y., Zhang, Z., Deng, K., Xia, Z., Gong, Q., Zhang, W., Zheng, X., Liu, Y., Yang, H., Zhou, D., Yu, D., Hou, J., Shi, Z., Chen, S., Chen, Z., Zhang, X., Yang, X. (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. U. S. A. 117(17), 9490–9496.
<https://doi.org/10.1073/pnas.2004168117>
14. FDA (2023) Investigational COVID-19 Convalescent Plasma. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma (last accessed in September 2024).
15. , J. C., Zänker, K., van Griensven, M., Schneider, M., Kindgen-Milles, D., Knoefel, W. T., Lichtenberg, A., Tamaskovics, B., Djiepmo-Njanang, F. J., Budach, W., Corradini, S., Ganswindt, U., Häussinger, D., Feldt, T., Schelzig, H., Bojar, H., Peiper, M., Bölke, E., Haussmann, J., Matuschek, C. (2020) The role of passive immunization in the age of SARS-CoV-2: An update. Eur. J. Med. Res. 25(1), 16.
<https://doi.org/10.1186/s40001-020-00414-5>
16. J. M., Rodríguez-García, S. C., Roy-Vallejo, E., Marcos-Jiménez, A., Sánchez-Alonso, S., Fernández-Díaz, C., Alcaraz-Serna, A., Mateu-Albero, T., Rodríguez-Cortes, P., Sánchez-Cerrillo, I., Esparcia, L., Martínez-Fleta, P., López-Sanz, C., Gabrie, L., Del Campo Guerola, L., Suárez-Fernández, C., Ancochea, J., Canabal, A., Albert, P., Rodríguez-Serrano, D. A., Aguilar, J. M., Del Arco, C., de Los Santos, I., García-Fraile, L., de la Cámara, R., Serra, J. M., Ramírez, E., Alonso, T., Landete, P., Soriano, J. B., Martín-Gayo, E., Fraile Torres, A., Zurita Cruz, N. D., García-Vicuña, R., Cardeñoso, L., Sánchez-Madrid, F., Alfranca, A., Muñoz-Calleja, C., González-Álvaro, I.; REINMUN-COVID Group (2021) IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. J. Allergy Clin. Immunol. 147(1), 72–80.e8.
<https://doi.org/10.1016/j.jaci.2020.09.018>
17. , G., Pesenti, A., Cecconi, M. (2020) Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: Early experience and forecast during an emergency response. JAMA 323(16), 1545–1546.
<https://doi.org/10.1001/jama.2020.4031>
18. , C., Rink, L., Fagin, U., Jabs, W. J., Kirchner, H. (2000) The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J. Immunol. Methods 235(1–2), 71–80.
<https://doi.org/10.1016/S0022-1759(99)00206-9>
19. , M., León, G., Segura, A., Meneses, F., Lomonte, B., Chippaux, J. P., Gutiérrez, J. M. (2005) Factors associated with adverse reactions induced by caprylic acid-fractionated whole IgG preparations: Comparison between horse, sheep and camel IgGs. Toxicon 46(7), 775–781.
<https://doi.org/10.1016/j.toxicon.2005.08.004>
20. , J., Kandeel, M., Hemida, M. G., Al-Mubarak, A. I. A. (2020) Antibody-based immunotherapeutic strategies for COVID-19. Pathogens 9(11), 917.
<https://doi.org/10.3390/pathogens9110917>
21. , S., Mina, M. J. (2019) Passive immunity for the treatment of influenza: Quality not quantity. Lancet Respir. Med. 7(11), 922–923.
<https://doi.org/10.1016/S2213-2600(19)30265-6>
22. , P., Day, M., Perkins, L., Moyer, L., Hewitt, K., Wells, A. (2020) A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit. Care 24(1), 128.
<https://doi.org/10.1186/s13054-020-2836-4>
23. , E. (1894) The antitoxin treatment of diphtheria: The preparation of Behring’s diphtheria antitoxin. Br. Med. J. 2(1772), 1393–1397.
<https://doi.org/10.1136/bmj.2.1772.1393>
24. , J. H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Kim, S. H., Kim, Y. J., Park, J. K., Chung, C. R., Kang, E. S., Cho, D., Müller, M. A., Drosten, C., Kang, C. I., Chung, D. R., Song, J. H., Peck, K. R. (2018) Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience. Antivir. Ther. 23(7), 617–622.
<https://doi.org/10.3851/IMP3243>
25. , B., Knoll, R., Bonaguro, L., ToVinh, M., Raabe, J., Astaburuaga-García, R., Schulte-Schrepping, J., Kaiser, K. M., Rieke, G. J., Bischoff, J., Monin, M. B., Hoffmeister, C., Schlabe, S., De Domenico, E., Reusch, N., Händler, K., Reynolds, G., Blüthgen, N., Hack, G., Finnemann, C., Nischalke, H. D., Strassburg, C. P., Stephenson, E., Su, Y., Gardner, L., Yuan, D., Chen, D., Goldman, J., Rosenstiel, P., Schmidt, S. V., Latz, E., Hrusovsky, K., Ball, A. J., Johnson, J. M., Koenig, P., Schmidt, F. I., Haniffa, M., Heath, J. R., Kümmerer, B. M., Keitel, V., Jensen, B., Stubbemann, P., Kurth, F., Sander, L. E., Sawitzki, B.; Deutsche COVID-19 OMICS Initiative (DeCOI); Aschenbrenner, A. C., Schultze, J. L., Nattermann, J. (2021) Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity 54(11), 2650–2669.e14.
<https://doi.org/10.1016/j.immuni.2021.09.002>
26. , R. L. (2020) Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 9, 72.
<https://doi.org/10.12688/f1000research.22211.2>
27. , K. (1937) Adult serum in measles. Br. Med. J. 2(4003), 612–613.
<https://doi.org/10.1136/bmj.2.4003.612>
28. , G., Segura, A., Herrera, M., Otero, R., França, F. O., Barbaro, K. C., Cardoso, J. L., Wen, F. H., de Medeiros, C. R., Prado, J. C., Malaque, C. M., Lomonte, B., Gutiérrez, J. M. (2008) Human heterophilic antibodies against equine immunoglobulins: Assessment of their role in the early adverse reactions to antivenom administration. Trans. R. Soc. Trop. Med. Hyg. 102(11), 1115–1119.
<https://doi.org/10.1016/j.trstmh.2008.04.038>
29. , R., Pérez Marc, G., Wappner, D., Coviello, S., Bianchi, A., Braem, V., Esteban, I., Caballero, M. T., Wood, C., Berrueta, M., Rondan, A., Lescano, G., Cruz, P., Ritou, Y., Fernández Viña, V., Álvarez Paggi, D., Esperante, S., Ferreti, A., Ofman, G., Ciganda, Á., Rodriguez, R., Lantos, J., Valentini, R., Itcovici, N., Hintze, A., Oyarvide, M. L., Etchegaray, C., Neira, A., Name, I., Alfonso, J., López Castelo, R., Caruso, G., Rapelius, S., Alvez, F., Etchenique, F., Dimase, F., Alvarez, D., Aranda, S. S., Sánchez Yanotti, C., De Luca, J., Jares Baglivo, S., Laudanno, S., Nowogrodzki, F., Larrea, R., Silveyra, M., Leberzstein, G., Debonis, A., Molinos, J., González, M., Perez, E., Kreplak, N., Pastor Argüello, S., Gibbons, L., Althabe, F., Bergel, E., Polack, F. P.; Fundación INFANT-COVID-19 Group (2021) Early high-titter plasma therapy to prevent severe Covid-19 in older adults. N. Engl. J. Med. 384(7), 610–618.
<https://doi.org/10.1056/NEJMoa2033700>
30. , D., Ni, B., Zhao, G., Jia, Z., Zhou, L., Pacal, M., Zhang, L., Zhang, S., Xing, L., Lin, Z., Wang, L., Li, J., Liang, Y., Shi, X., Zhao, T., Zou, L., Wu, Y., Wang, X. (2007) Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab’)2. Viral Immunol. 20(3), 495–502.
<https://doi.org/10.1089/vim.2007.0038>
31. , J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F. M., Lim, W. S., Makki, S., Rooney, K. D., Nguyen-Van-Tam, J. S., Beck, C. R.; Convalescent Plasma Study Group (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J. Infect. Dis. 211(1), 80–90.
<https://doi.org/10.1093/infdis/jiu396>
32. , L. W., Redden, W. R. (1918) The use of convalescent human serum in influenza pneumonia – A preliminary report. Am. J. Public Health (N. Y.) 8(10), 741–744.
<https://doi.org/10.2105/AJPH.8.10.741>
33. , G., Rezza, G., Brusaferro, S. (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323(18), 1775–1776.
34. , X., Zhou, P., Fan, T., Wu, Y., Zhang, J., Shi, X., Shang, W., Fang, L., Jiang, X., Shi, J., Sun, Y., Zhao, S., Gong, R., Chen, Z., Xiao, G. (2020) Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro. Antiviral Res. 182, 104868.
<https://doi.org/10.1016/j.antiviral.2020.104868>
35. , L., Park, Y. J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., Acton, O. J., Jaconi, S., Guarino, B., Minola, A., Zatta, F., Sprugasci, N., Bassi, J., Peter, A., De Marco, A., Nix, J. C., Mele F., Jovic, S., Fernandez Rodriguez, B., Gupta, S. V., Jin, F., Piumatti, G., Lo Presti, G., Franzetti Pellanda, A., Biggiogero, M., Tarkowski, M., Pizzuto, M. S., Cameroni, E., Havenar-Daughton, C., Smithey, M., Hong, D., Lepori, V., Albanese, E., Ceschi, A., Bernasconi, E., Elzi, L., Ferrari, P., Garzoni, C., Riva, A., Snell, G., Sallusto, F., Fink, K., Virgin, H. W., Lanzavecchia, A., Corti, D., Veesler, D. (2020) Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183(4), 1024–1042.e21.
<https://doi.org/10.1016/j.cell.2020.09.037>
36. , V., Iannizzi, C., Chai, K. L., Valk, S. J., Kimber, C., Dorando, E., Monsef, I., Wood, E. M., Lamikanra, A. A., Roberts, D. J., McQuilten, Z., So-Osman, C., Estcourt, L. J., Skoetz, N. (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A living systematic review. Cochrane Database Syst. Rev. 7(7), CD013600.
37. , T., Denizot, M., Pannetier, D., Nguyen, L., Pasquier, A., Raoul, H., Saluzzo, J. F., Kobinger, G., Veas, F., Herbreteau, C. H. (2019) In vitro characterization and in vivo effectiveness of Ebola virus specific equine polyclonal F(ab’)2. J. Infect. Dis. 220(1), 41–45.
<https://doi.org/10.1093/infdis/jiz068>
38. , J. D., Guarner, J. (2020) Convalescent plasma to treat COVID-19: Possibilities and challenges. JAMA 323(16), 1561–1562.
<https://doi.org/10.1001/jama.2020.4940>
39. , C., Díaz, P., D’Suze, G. (2008) On the presence of antibodies against bovine, equine and poultry immunoglobulins in human IgG preparations, and its implications on antivenom production. Toxicon 51(1), 10–16.
<https://doi.org/10.1016/j.toxicon.2007.06.009>
40. , J. H. (2020) Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 368, m1256.
<https://doi.org/10.1136/bmj.m1256>
41. , P., de Lamballerie, X., Morel, P., Gallian, P., Lacombe, K., Yazdanpanah, Y. (2020) Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how? Vox Sang. 115(6), 488–494.
<https://doi.org/10.1111/vox.12926>
42. , X., Ni, B., Du, X., Zhao, G., Gao, W., Shi, X., Zhang, S., Zhang, L., Wang, D., Luo, D., Xing, L., Jiang, H., Li, W., Jiang, M., Mao, L., He, Y., Xiao, Y., Wu, Y. (2005) Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody. Antiviral Ther. 10(5), 681–690.
<https://doi.org/10.1177/135965350501000504>
43. , M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F., Xia, X., Lv, T. (2020) Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J. Med. Virol. 92(10), 1890–1901.
<https://doi.org/10.1002/jmv.25882>
44. , Y., Wang, C., Qiu, B., Li, C., Wang, H., Jin, H., Gai, W., Zheng, X., Wang, T., Sun, W., Yan, F., Gao, Y., Wang, Q., Yan, J., Chen, L., Perlman, S., Zhong, N., Zhao, J., Yang, S., Xia, X. (2017) Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antiviral Res. 137, 125–130.
<https://doi.org/10.1016/j.antiviral.2016.11.016>
45. , L., Ni, B., Luo, D., Zhao, G., Jia, Z., Zhang, L., Lin, Z., Wang, L., Zhang, S., Xing, L., Li, J., Liang, Y., Shi, X., Zhao, T., Zhou, L., Wu, Y., Wang, X. (2007) Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice. Int. Immunopharmacol. 7(3), 392–400.
<https://doi.org/10.1016/j.intimp.2006.10.009>
